PE20231101A1 - Compuestos para su uso en afecciones autoinmunitarias - Google Patents
Compuestos para su uso en afecciones autoinmunitariasInfo
- Publication number
- PE20231101A1 PE20231101A1 PE2022001801A PE2022001801A PE20231101A1 PE 20231101 A1 PE20231101 A1 PE 20231101A1 PE 2022001801 A PE2022001801 A PE 2022001801A PE 2022001801 A PE2022001801 A PE 2022001801A PE 20231101 A1 PE20231101 A1 PE 20231101A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- optionally substituted
- alkenyl
- alkyl
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001363 autoimmune Effects 0.000 title 1
- 102000002689 Toll-like receptor Human genes 0.000 abstract 2
- 108020000411 Toll-like receptor Proteins 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 abstract 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Refiere a un compuesto de formula general (I) o una sal o estereoisomero del mismo, para el tratamiento de una afeccion inmunitaria caracterizada por el aumento de la senalizacion de uno o mas receptores del tipo Toll (TLR), en donde X se selecciona entre O y NH; Y se selecciona entre CO y -COCH(CH3)CO-; n y p se seleccionan entre 0-1; q se selecciona entre 0,1 y 2; R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 y R16 se seleccionan de hidrogeno, alquilo C1-C6, alquenilo C2-C6 y alquinilo C2-C6 opcionalmente sustituidos, entre otros, asimismo, R6 y R7 y/o R13 y R14, junto a los atomos de C o N a los que estan unidos, forman un grupo heterociclico opcionalmente sustituido; y R17, Ra, Rb y Rc se seleccionan de alquilo C1-C12, alquenilo C2-C12, arilo y alquinilo C2-C12 opcionalmente sustituidos. Ademas la presente menciona una composicion farmaceutica a base de dicho compuesto y un portador farmaceuticamente aceptable y el uso de dicho compuesto en la fabricacion de un medicamento para el tratamiento en particular de la artritis reumatoide, junto a un metodo de aplicacion.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382815 | 2020-09-16 | ||
| EP20382814 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| PCT/EP2021/055142 WO2021175829A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in autoimmune conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231101A1 true PE20231101A1 (es) | 2023-07-18 |
Family
ID=74732952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001801A PE20231101A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en afecciones autoinmunitarias |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230158104A1 (es) |
| EP (1) | EP4114432A1 (es) |
| JP (1) | JP2023517537A (es) |
| KR (1) | KR20220148896A (es) |
| CN (1) | CN115867286A (es) |
| AU (1) | AU2021229592A1 (es) |
| BR (1) | BR112022017129A2 (es) |
| CA (1) | CA3169557A1 (es) |
| CL (1) | CL2022002397A1 (es) |
| CO (1) | CO2022014023A2 (es) |
| IL (1) | IL296070A (es) |
| MX (1) | MX2022010925A (es) |
| PE (1) | PE20231101A1 (es) |
| TW (1) | TW202146039A (es) |
| UY (1) | UY39111A (es) |
| WO (1) | WO2021175829A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| DK1276491T3 (da) | 2000-04-07 | 2007-02-05 | Univ Pennsylvania | Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| EP1613338A4 (en) | 2003-03-21 | 2009-06-24 | Madeleine M Joullie | TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
-
2020
- 2020-03-02 US US17/908,532 patent/US20230158104A1/en active Pending
-
2021
- 2021-03-02 MX MX2022010925A patent/MX2022010925A/es unknown
- 2021-03-02 CN CN202180018708.8A patent/CN115867286A/zh active Pending
- 2021-03-02 TW TW110107294A patent/TW202146039A/zh unknown
- 2021-03-02 EP EP21708018.3A patent/EP4114432A1/en active Pending
- 2021-03-02 PE PE2022001801A patent/PE20231101A1/es unknown
- 2021-03-02 UY UY0001039111A patent/UY39111A/es unknown
- 2021-03-02 AU AU2021229592A patent/AU2021229592A1/en active Pending
- 2021-03-02 BR BR112022017129A patent/BR112022017129A2/pt unknown
- 2021-03-02 IL IL296070A patent/IL296070A/en unknown
- 2021-03-02 KR KR1020227034324A patent/KR20220148896A/ko unknown
- 2021-03-02 JP JP2022552947A patent/JP2023517537A/ja active Pending
- 2021-03-02 WO PCT/EP2021/055142 patent/WO2021175829A1/en active Application Filing
- 2021-03-02 CA CA3169557A patent/CA3169557A1/en active Pending
-
2022
- 2022-09-02 CL CL2022002397A patent/CL2022002397A1/es unknown
- 2022-09-30 CO CONC2022/0014023A patent/CO2022014023A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022017129A2 (pt) | 2022-10-11 |
| TW202146039A (zh) | 2021-12-16 |
| KR20220148896A (ko) | 2022-11-07 |
| CO2022014023A2 (es) | 2022-11-18 |
| JP2023517537A (ja) | 2023-04-26 |
| US20230158104A1 (en) | 2023-05-25 |
| CN115867286A (zh) | 2023-03-28 |
| CA3169557A1 (en) | 2021-09-10 |
| CL2022002397A1 (es) | 2023-06-30 |
| AU2021229592A1 (en) | 2022-09-29 |
| UY39111A (es) | 2021-09-30 |
| MX2022010925A (es) | 2022-09-29 |
| IL296070A (en) | 2022-11-01 |
| WO2021175829A1 (en) | 2021-09-10 |
| EP4114432A1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060562A1 (es) | Derivados de amino-piperidina como agonistas de los receptores de melanocortina mc3 y/o mc4 | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| AR046781A1 (es) | Derivados de imidazoquinolinas. composiciones farmaceuticas. | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| ECSP066760A (es) | Derivado de 4-oxopirimidina de anillos condensados | |
| CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR061581A1 (es) | Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c. | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| CO5261616A1 (es) | Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| PE20020483A1 (es) | Peptidos ciclicos selectivos como agonistas de los receptores de melanocortina 4 | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| AR081758A1 (es) | Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas | |
| AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| ES2578302T3 (es) | Compuestos de 5,6-dihidro-1H-piridin-2-ona | |
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton |